Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

T. Rowe Price Health Sciences Fund (PRHSX)

Net Asset Value
1 Day
Overall Morningstar Rating
Style or Category
No Load
Sales Expenses
Expense Ratio
Above Average
Morningstar Risk Rating™
Investment Objective The investment seeks long-term capital appreciation. The fund will normally invest at least 80% of its net assets (including any borrowings for investment purposes) in the common stocks of companies engaged in the research, development, production, or distribution of products or services related to health care, medicine, or the life sciences (collectively termed "health sciences"). While the fund can invest in companies of any size, the majority of fund assets are expected to be invested in large- and mid-capitalization companies.


1 month-12.10% 3 years+19.28%
3 months-16.02% 5 years+20.89%
1 year-10.76% Since inception+14.51%
Data through --

Peer Comparisonvs. Health

Performance 5-yr return+20.89%+21.20%
Expense ratio0.77%1.36%
Risk 5 year sharpe ratio1.331.12
Net assets$12.0B$3.4B
Average market cap$24.4B$36.5B
Average P/E22.722.4
Portfolio turnover42%42%

There are thousands of mutual funds to choose from. Get Money Magazine’s picks in all major categories.

Fund Management and Purchase Info

Fund familyT. Rowe Price
Fund manager & tenureTaymour Tamaddon / 2 Years
Minimal initial investment$2,500.00
Minimum IRA investment$1,000.00


U.S. stock89.84%
International stock6.12%
Fixed income1.36%
Top 5 Sectors
Portfolio weighting
Healthcare 93.76%
Industrial materials 0.91%
Consumer service 0.89%
Financial service 0.38%
Telecommunication 0.19%
Top 10 Holdings
Portfolio weighting
AGN Allergan5.96%
ALXN Alexion Pharmaceuticals Inc4.57%
UNH UnitedHealth3.69%
HUM Humana Inc3.41%
AET Aetna3.15%
CI Cigna Corp2.85%
GILD Gilead Sciences2.72%
TMO Thermo Fisher Scientific Inc2.72%
INCY Incyte Corp2.55%
REGN Regeneron Pharmaceuticals2.51%

Partner Offers